Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com - Cantor Fitzgerald raised its price target on Abbvie (NYSE:ABBV) to $215.00 from $210.00 on Wednesday, while maintaining an Overweight rating on the pharmaceutical company’s stock. The healthcare giant, with a market capitalization of $354.5 billion, maintains a strong financial health score according to InvestingPro data, supported by consistent dividend payments and stable growth metrics.
The price target adjustment follows Abbvie’s quarterly results, which Cantor Fitzgerald described as "one of the strongest prints" in the sector, with Skyrizi sales exceeding high market expectations. This performance aligns with broader analyst sentiment, as InvestingPro data shows 14 analysts have recently revised their earnings expectations upward, with price targets ranging from $170 to $255.
Abbvie has raised its top-line guidance following the strong performance, with Cantor Fitzgerald suggesting the company may further increase its longer-term Immunology guidance in early 2026.
The research firm views Abbvie as a potential beneficiary from Lilly’s recent reset, positioning it as an alternative growth name with limited clinical or downside risk in the near term.
Cantor Fitzgerald’s price target increase reflects expectations for higher near-term and mid-term sales of Skyrizi, Rinvoq, and Vraylar, along with potential value from Abbvie’s DACRA asset, ABBV-295, which approaches a phase 1 read-out early next year.
In other recent news, AbbVie reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of $2.97, slightly above the forecast of $2.96. The company also exceeded revenue forecasts, posting $15.4 billion compared to the anticipated $14.99 billion. Following this earnings beat, AbbVie raised its full-year guidance, despite challenges related to its Humira product. In another development, AbbVie announced a $195 million investment to expand its active pharmaceutical ingredient manufacturing capabilities at its North Chicago plant. This expansion is part of the company’s broader plan to invest over $10 billion in U.S. capital projects over the next decade. On the analyst front, Piper Sandler initiated coverage of AbbVie with an Overweight rating, citing the company’s favorable position regarding loss of exclusivity exposure. Bernstein SocGen Group reiterated its Market Perform rating and maintained a $203.00 price target following the earnings report. These developments reflect a period of strategic growth and positive analyst sentiment for AbbVie.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.